The J.P. Morgan Q3 2025 biopharma and medtech report, using DealForma data, highlights mixed venture investment trends, strong M&A activity, modest IPO recovery, and continued focus on large, late-stage licensing deals across both sectors. Download the biopharma and medtech reports here
